manufacturing capacity and capability, market concentration, or
just-in-time inventory practices that result in minimal product
inventory being on hand at any given time. Manufacturers could
consider opportunities for building redundant manufacturing
capacity, holding spare capacity, or increasing inventory levels to
lower the risks of shortages. Other stakeholders might explore
how to incentivize such practices.
Price escalation in the face of drug shortages exacerbates
the problem. The FDA is asking key stakeholders to explore
mitigation activities to minimize gray market activities.
The agency has taken positive steps to address the drug short-
ages issue. Notification to the FDA by drug manufacturers of
potential supply disruptions has increased six-fold since the pres-
idential directive. Now, status of drug shortages can be found on
the FDA’s website and is searchable alphabetically. It remains to be
seen how earnest industry will be in addressing these issues given
the public’s quality blind spot. The public assumes our drugs are
safe and effective regardless of any data to the contrary. The agen-
cy is in a difficult position to send a consistent quality message
to the industry when it has to deal with potential drug shortage
considerations, on a case-by-case basis. However, the strategic
plan by FDA is a solid step toward establishing systems that will, if
nothing else, provide an early warning so a potential remediation
may be identified to avoid the shortage.
References
1. USGAO - http://www.gao.gov/assets/590/586979.pdf
2. FDASIA - http://www.gpo.gov/fdsys/pkg/BILLS-
112s3187enr/pdf/BILLS-112s3187enr.pdf
3. Presidential Executive Order 13588, 13589
4. FDA’s Strategic Plan for Preventing and Mitigating Drug
Shortages, October 2013 - http://www.fda.gov/downloads/
drugs/drugsafety/drugshortages/ucm372566.pdf
Bikash Chatterjee, President and CTO, Pharmatech
Associates, has been involved in the biopharmaceutical, pharmaceutical, medical device, and diagnostics industry for over 30
years. His expertise includes site selection, project management,
design, and validation of facilities for U.S. and European regulatory requirements.
Sterilization Solutions
®
CONTRACT AND ON-SITE
PERACETIC ACID STERILIZATION
REVOX™ ADVANTAGES
• ROOM TEMPERATURE
• NO CHEMICAL RESIDUALS
• FAST TURNAROUND
• EXCELLENT COMPATIBILITY
• PROCESSING OPTIONS
REVOX® is a registered trademark of Medivators Inc., A Cantel Medical Company